DeGolyer Donald W 4

4 · TYME TECHNOLOGIES, INC. · Filed Sep 16, 2022

Form 4

Period: 2022-09-16

Director

Transactions

Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−100,000→ 0 total
Exercise: $2.90Exp: 2028-05-24→ Common Stock (100,000 underlying)
Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−50,000→ 0 total
Exercise: $1.18Exp: 2029-08-22→ Common Stock (50,000 underlying)
Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−50,000→ 0 total
Exercise: $2.33Exp: 2028-08-26→ Common Stock (50,000 underlying)
Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−88,000→ 0 total
Exercise: $1.10Exp: 2031-08-23→ Common Stock (88,000 underlying)
Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−65,000→ 0 total
Exercise: $1.22Exp: 2030-08-19→ Common Stock (65,000 underlying)
Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−88,000→ 0 total
Exercise: $0.31Exp: 2032-08-23→ Common Stock (88,000 underlying)

Footnotes (6)

[F1]This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 4,382 shares of Syros common stock for $66.18 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split").
[F2]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split.
[F3]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split.
[F4]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split.
[F5]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split.
[F6]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.

Documents

1 file